President-elect Donald Trump has announced he wants to appoint vaccine sceptic Robert F Kennedy Jr as the head of the US ...

The Dow Jones Industrial Average (DJIA), one of the three main Wall Street benchmarks, succumbed to selling pressure in early ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

The U.S. Food and Drug Administration approved the Keytruda combination in malignant pleural mesothelioma in September. Keytruda, a cancer drug that harnesses a patient's immune system to fight tumors ...

VEGF bispecifics. | Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued ...

Pharmaceutical stocks took a steep plunge in the wake of President Donald Trumps appointment of Robert F. Kennedy Jr. as ...

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.

The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...

MERCK & Co licenced an experimental cancer antibody from a closely held Chinese company in a deal worth US$588 million ...

Summit and Akeso's ivonescimab attracted headlines earlier this year when it was shown to be more effective than anti-PD-1 ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...